
Vectech is an innovative company focused on AI-driven entomology for professionals. Their core product, IDX, is the world's first AI diagnostic entomology system designed to identify over 43 mosquito species and 17 tick species. This technology aims to improve pest control by providing accurate data for targeted interventions, helping to combat vector-borne diseases which affect a significant portion of the global population. Vectech's solutions cater to mosquito control districts, international health organizations, and research institutions worldwide. The company was founded to address the need for better entomological data during the Zika epidemic and has since developed approaches to reduce the cost and expertise required for specimen identification, potentially revolutionizing mosquito control practices.

Vectech is an innovative company focused on AI-driven entomology for professionals. Their core product, IDX, is the world's first AI diagnostic entomology system designed to identify over 43 mosquito species and 17 tick species. This technology aims to improve pest control by providing accurate data for targeted interventions, helping to combat vector-borne diseases which affect a significant portion of the global population. Vectech's solutions cater to mosquito control districts, international health organizations, and research institutions worldwide. The company was founded to address the need for better entomological data during the Zika epidemic and has since developed approaches to reduce the cost and expertise required for specimen identification, potentially revolutionizing mosquito control practices.
Founded: 2019
Headquarters: Baltimore, MD
Product: AI-powered entomology platform for mosquito and tick identification
Tech focus: Computer vision / AI diagnostics for vectors
Funding signals: Grants and accelerator support (NIH SBIR, NSF, Techstars, Maryland Innovation Initiative)
Vector surveillance and entomological diagnostics for disease prevention and pest control.
2019
Biotechnology
150000
Pre-seed investment announced August 13, 2020.
295000
NIH SBIR Phase I award reported in public summaries.
20000
Recorded accelerator/seed entry in Jan 2023.
“Support from accelerators, state innovation programs, and federal grants (Techstars, MassChallenge, TEDCO, Maryland Innovation Initiative, NIH, NSF, USDA)”